Actinium
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 49
- Market Cap
- $61.9M
- Introduction
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
- Conditions
- Relapsed Adult AMLAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Registration Number
- NCT03932318
Venetoclax and Lintuzumab-Ac225 in AML Patients
- Conditions
- Acute Myeloid LeukemiaRelapsed Adult AML
- Interventions
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03867682
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT02998047
- Locations
- 🇺🇸
Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer CEnter, New York, New York, United States
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myelogenous LeukemiaLeukemia, Acute MyelogenousAcute Myeloid LeukemiaLeukemia, Myeloid, AcuteMyelogenous Leukemia, AcuteAMLMyeloid Leukemia, AcuteBone Marrow TransplantLeukemia, Acute Myeloid
- Interventions
- Drug: Iomab-BDrug: Conventional CareProcedure: HCT
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT02665065
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
🇺🇸Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
- Conditions
- AML
- Interventions
- Drug: Cytarabine (Phase 1 only)Biological: Lintuzumab-Ac225Drug: Furosemide (Phase 1 only)Drug: Spironolactone
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02575963
- Locations
- 🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Columbia University Medical, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸St. Francis Cancer Center, Greenville, South Carolina, United States